<DOC>
	<DOCNO>NCT01397305</DOCNO>
	<brief_summary>The purpose study determine whether optimal dose [ 6R ] 5,10-methylenetetrahydrofolate ( Modufolin ) combination pemetrexed effective pre-operative treatment patient resectable rectal cancer .</brief_summary>
	<brief_title>An Extended Feasibility Phase I/II Study Methylenetetrahydrofolate Pemetrexed Single Agent , Given Neoadjuvant Treatment Patients With Resectable Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antimetabolites , Antineoplastic</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Pathological/ cytological diagnosis adenocarcinoma rectum . Patients must operable rectal cancer amenable surgery . No prior therapy rectal cancer Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 Adequate organ function Patient compliance geographic proximity allow adequate followup For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen 3 month treatment ; must negative serum urine pregnancy test must lactate . For men : Must surgically sterile compliant contraceptive regimen 3 month treatment . Estimated life expectancy least 12 week Signed informed consent At least 18 year age Concurrent administration antitumor therapy . Treatment within last 30 day drug receive regulatory approval indication time study entry . Serious concomitant systemic disorder ( e.g. , active infection include HIV , cardiac disease ) opinion investigator would compromise patient 's ability complete study . Have previously complete withdrawn study study investigate pemetrexed . Are pregnant breastfeeding . Second primary malignancy clinically detectable time consideration study enrollment . History significant neurological mental disorder , include seizure dementia . Inability interrupt aspirin nonsteroidal antoinflammatory drug ( NSAIDs ) Presence clinically relevant thirdspace fluid collection control drainage procedure prior study entry . Inability unwillingness give 5,10methylenetetrahydrofolate , vitamin B12 dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>5,10-methylenetetrahydrofolate</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Rectal Neoplasms</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Folic Acid Antagonists</keyword>
	<keyword>Antimetabolites , Antineoplastic</keyword>
	<keyword>Antimetabolites</keyword>
</DOC>